NORTH AMERICA BOTULINUM TOXIN MARKET FORECAST 2023-2032

The North America botulinum toxin market growth analysis evaluation entails a thorough study of Canada and the United States. Over the last two decades, medical aesthetic technology has advanced rapidly in the United States, offering patients a wide range of products and solutions. In 2019, according to the American Society for Aesthetic Plastic Surgery, 1,712,994 procedures were performed with botulinum toxin, with an injection to treat facial wrinkles considered the country’s most frequently performed cosmetic procedure. Therefore, the use of botulinum toxins in aesthetic medicine has significantly increased. 

Botulinum toxin injections are approved by the United States Food and Drug Administration for treating frown lines, crow’s feet, and horizontal forehead lines and are associated with high patient satisfaction and few adverse effects. In 2019 Daewoong Pharmaceutical launched Nabota, its botulinum toxin strain, becoming the first South Korean botulinum toxin product sold in the United States market. These approvals and launches have contributed to the overall growth of the market.

The North America botulinum toxin market segmentation assessment includes user demographic, application, end-user, and type. Market by user demographic covers women and men.

The women’s market dominates the global market for botulinum toxin, and it is predicted to continue growing during the forecast period. This is due to the increasing trend among middle-aged women for skin rejuvenation and aesthetic surgeries. In 2020, more than 4.1 million women received botulinum toxin surgery, according to data from the Aesthetic Society. Additionally, women experience visible signs of aging, such as forehead wrinkles, frown lines, and crow’s feet, which can be reduced with products containing botulinum toxin.

The desire for a more youthful appearance drives the growing interest in cosmetic treatments, particularly among women over 40 in developed nations. The market for botulinum toxin is expected to expand due to this trend. In 2020, more than 2.5 million women between the ages of 40 and 54 received botulinum toxin treatments worldwide, indicating significant potential for market growth. Therefore, the increased focus on aesthetic appearances, such as lip treatments for women, particularly in developed countries, is expected to fuel the expansion of the market.

Major market players in the North America botulinum toxin market include Revance Therapeutics Inc, AbbVie Inc, etc.

AbbVie Inc is a global biopharmaceutical company developing innovative drugs for complex and chronic diseases. The company’s robust pipeline includes treatments for women’s health, cystic fibrosis, various cancers, neurological disorders, and autoimmune diseases. AbbVie markets its products directly to healthcare facilities, government agencies, specialty pharmacies, and independent retailers worldwide through its distribution centers and warehouses. The company is headquartered in Illinois, United States. 

BOTOX, one of AbbVie’s products, is a highly effective treatment for various medical conditions, including adult bladder dysfunction, chronic migraine, spasticity, blepharospasm, and strabismus. The injection, administered intramuscularly, intradetrusor or intradermally, contains onabotulinumtoxinA and is widely used by healthcare professionals globally. With its proven efficacy, BOTOX has become popular for patients seeking relief from various medical conditions.